$0.19
2.34% day before yesterday
Nasdaq, Dec 27, 10:11 pm CET
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Aditx Therapeutics Inc Stock price

$0.19
-0.16 46.05% 1M
-55.41 99.66% 6M
-265.01 99.93% YTD
-188.21 99.90% 1Y
-54,991.81 100.00% 3Y
-404,799.81 100.00% 5Y
-404,799.81 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.00 2.34%
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Key metrics

Market capitalization $2.68m
Enterprise Value $12.35m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 58.81
P/S ratio (TTM) P/S ratio 12.76
P/B ratio (TTM) P/B ratio 0.02
Revenue growth (TTM) Revenue growth -71.70%
Revenue (TTM) Revenue $210.00k
EBIT (operating result TTM) EBIT $-30.16m
Free Cash Flow (TTM) Free Cash Flow $-13.92m
Cash position $330.00k
EPS (TTM) EPS $-981.65
P/E forward 0.00
P/S forward 1.07
EV/Sales forward 6.31
Short interest 10.42%
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

Buy
100%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.21 0.21
72% 72%
100%
- Direct Costs 1.43 1.43
18% 18%
681%
-1.21 -1.21
163% 163%
-576%
- Selling and Administrative Expenses 14 14
27% 27%
6,605%
- Research and Development Expense 14 14
148% 148%
6,900%
-30 -30
17% 17%
-14,086%
- Depreciation and Amortization 0.58 0.58
2% 2%
276%
EBIT (Operating Income) EBIT -30 -30
17% 17%
-14,364%
Net Profit -40 -40
36% 36%
-19,138%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
17 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (“Adimune”), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a ma...
Neutral
PRNewsWire
about one month ago
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections   — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financia...
Neutral
Business Wire
about 2 months ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility, as well as its outstanding number of shares. Equity Issuance Update as of End...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 47
Founded 2017
Website www.aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today